Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5843876 | Pharmacology & Therapeutics | 2016 | 15 Pages |
Abstract
The present review describes connexin structure and organization in gap junctions. It focuses on connexins in the lung, including pulmonary bronchial and arterial beds, by looking at their expression, regulation and physiological functions. This work also addresses the issue of connexin expression alteration in various pulmonary inflammatory diseases and describes how targeting connexin-based gap junctions with pharmacological tools, synthetic blocking peptides or genetic approaches, may open new therapeutic perspectives in the treatment of these diseases.
Keywords
CK1cGMPMCTmonocrotalinepKaIP3CFTRPKCinositol triphosphateNF-κBconnexinsPDE5CD73Th2cdc2PASMCPAECTGF-β5-HTshRNAADMALPSMEF2PAH5-hydroxytryptamine or serotonincAMPMAPKshort interfering RNAshort hairpin RNAROSsiRNAVE-cadherinCyclic adenosine monophosphategap junctionsinflammationVascular endothelial-cadherintransforming growth factor-βtumor necrosis factor-αasymmetric dimethylargininecystic fibrosis transmembrane conductance regulatorLungcell division cycle 2pulmonary artery smooth muscle cellsPulmonary artery endothelial cellszonula occludensTNF-αnuclear factor-κBPhosphodiesterase 5Pulmonary arterial hypertensionlipopolysaccharidecyclic guanosine monophosphateNitric oxideChronic hypoxiahypoxic pulmonary vasoconstrictionHPVPulmonary hypertensionprotein kinase AProtein kinase Cmitogen-activated protein kinasecasein kinase 1connexinReactive oxygen species
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Véronique Freund-Michel, Bernard Muller, Roger Marthan, Jean-Pierre Savineau, Christelle Guibert,